newsfilter
← Latest News
Business Wire·

Pfizer to Acquire Metsera and its Next-Generation Obesity Portfolio

Proposed acquisition to add four highly differentiated clinical-stage incretin and amylin programs to Pfizer's pipeline Transaction valued at $47.50 per Metsera share in cash upon closing, for an initial enterprise